- Home
- AGAE vs MGNX Comparison
AGAE vs MGNX Comparison
Compare AGAE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- MGNX
- Stock Information
- Founded
- AGAE 2017
- MGNX 2000
- Country
- AGAE United States
- MGNX United States
- Employees
- AGAE N/A
- MGNX N/A
- Industry
- AGAE Cable & Other Pay Television Services
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- AGAE Telecommunications
- MGNX Health Care
- Exchange
- AGAE Nasdaq
- MGNX Nasdaq
- Market Cap
- AGAE 84.7M
- MGNX 97.2M
- IPO Year
- AGAE N/A
- MGNX 2013
- Fundamental
- Price
- AGAE $3.01
- MGNX $1.36
- Analyst Decision
- AGAE
- MGNX Hold
- Analyst Count
- AGAE 0
- MGNX 9
- Target Price
- AGAE N/A
- MGNX $5.33
- AVG Volume (30 Days)
- AGAE 646.6K
- MGNX 378.7K
- Earning Date
- AGAE 06-06-2025
- MGNX 05-13-2025
- Dividend Yield
- AGAE N/A
- MGNX N/A
- EPS Growth
- AGAE N/A
- MGNX N/A
- EPS
- AGAE N/A
- MGNX N/A
- Revenue
- AGAE $9,256,023.00
- MGNX $154,050,000.00
- Revenue This Year
- AGAE N/A
- MGNX N/A
- Revenue Next Year
- AGAE N/A
- MGNX $45.52
- P/E Ratio
- AGAE N/A
- MGNX N/A
- Revenue Growth
- AGAE 36.15
- MGNX 255.31
- 52 Week Low
- AGAE $0.66
- MGNX $0.99
- 52 Week High
- AGAE $3.79
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- AGAE 70.08
- MGNX 39.88
- Support Level
- AGAE $1.77
- MGNX $1.44
- Resistance Level
- AGAE $3.79
- MGNX $1.58
- Average True Range (ATR)
- AGAE 0.48
- MGNX 0.11
- MACD
- AGAE 0.12
- MGNX -0.02
- Stochastic Oscillator
- AGAE 66.67
- MGNX 17.65
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.